| Autor: |
Lin J; Schulich School of Medicine & Dentistry, Western University, London, ON N6A 3K7, Canada., Welch S; Division of Medical Oncology, Department of Oncology, Western University, London, ON N6A 3K7, Canada., Sanatani M; Division of Medical Oncology, Department of Oncology, Western University, London, ON N6A 3K7, Canada., Ramadan S; Postgraduate Medical Education, Department of Oncology, Western University, London, ON N6A 3K7, Canada. |
| Jazyk: |
angličtina |
| Zdroj: |
Current oncology (Toronto, Ont.) [Curr Oncol] 2024 Jan 19; Vol. 31 (1), pp. 558-565. Date of Electronic Publication: 2024 Jan 19. |
| DOI: |
10.3390/curroncol31010039 |
| Abstrakt: |
We present the case of a 75-year-old female with simultaneous EGFR-mutated stage IV lung cancer and advanced BRCA2-mutated ovarian cancer, treated with a unique regimen. In this case report, the patient was treated with alternating months of osimertinib and olaparib to control her lung and ovarian cancers, respectively. When both diseases showed progression, the patient underwent a trial of concurrent therapy with both drugs, yet this was discontinued due to patient-reported adverse side effects. Combination targeted drug therapy may be required to treat complex diagnoses such as dual malignancies. However, combination drug therapy consisting of osimertinib and olaparib has not previously been explored. This case report represents the first to demonstrate osimertinib and olaparib combination therapy as a unique treatment regimen for concurrent lung and ovarian cancers. These two drugs can either be given in an alternating way or given together, short-term, with a higher but tolerable toxicity profile. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
